Filana Therapeutics (FLNA) Free Cash Flow Growth (3y) (2013 - 2026)
Filana Therapeutics (FLNA) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 21.16% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.09% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 80.69% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -23.92% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 8.92% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -4.45% |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.27% |
| Mar 31, 2026 | 13.21% |
| Dec 31, 2025 | 21.13% |
| Sep 30, 2025 | 34.83% |
| Jun 30, 2025 | 26.65% |
| Mar 31, 2025 | 22.07% |
| Dec 31, 2024 | -96.42% |
| Sep 30, 2024 | 20.75% |
| Jun 30, 2024 | -52.71% |
| Mar 31, 2024 | -102.42% |
| Dec 31, 2023 | -166.97% |
| Sep 30, 2023 | -130.40% |
| Jun 30, 2023 | -187.06% |
| Mar 31, 2023 | -125.06% |
| Dec 31, 2022 | -229.05% |
| Sep 30, 2022 | -214.49% |
| Jun 30, 2022 | -177.14% |
| Mar 31, 2022 | -237.70% |
| Dec 31, 2021 | -142.80% |
| Sep 30, 2021 | -194.84% |